445026-29-9

Upstream product

• 51446-31-2 4-fluoro-3-hydroxybenzoic acid 
• 1000207-63-5 ethyl 3-ethoxy-4-fluorobenzoate 
• 112204-58-7 5-Bromo-2-fluorophenol 
• 900174-64-3 4-Bromo-2-ethoxy-1-fluorobenzene 
• 124-38-9 carbon dioxide 

Downstream Products

• 1607022-86-5 5-(3-ethoxy-4-fluorophenyl)-3-(5-methyloxazol-2-yl)-4H,7H-pyrazolo[1,5-a]pyrimidin-7-one 
• 1607023-28-8 5-(3-ethoxy-4-fluorophenyl)-3-(1-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1607024-31-6 ethyl 3-(3-ethoxy-4-fluorophenyl)-3-oxopropanoate 
• 445019-49-8 N-(3-ethoxy-4-fluorobenzoyl)-D-serine methyl ester 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC

Deacetylation of uridyldiphospho-3-O-(R-hydroxydecanoyl)-N-acetylglucosamine by LpxC is the first committed step in the Pseudomonas aeruginosa biosynthetic pathway to lipid A; homologous enzymes are found widely among Gram-negative bacteria. As an essential enzyme for which no inhibitors have yet been reported, the P. aeruginosa LpxC represents a highly attractive target for a novel antibacterial drug. We synthesized several focused small-molecule libraries, each composed of a variable aromatic ring, one of four heterocyclic/spacer moieties, and a hydroxamic acid and evaluated the LpxC inhibition of these compounds against purified P. aeruginosa enzyme. To ensure that the in vitro assay would be as physiologically relevant as possible, we synthesized a tritiated form of the specific P. aeruginosa glycolipid substrate and measured directly the enzymatically released acetate. Several of our novel compounds, predominantly those having fluorinated substituents on the aromatic ring and an oxazoline as the heterocyclic moiety, demonstrated in vitro IC50 values less than 1 μM. We now report the synthesis and in vitro evaluation of these P. aeruginosa LpxC inhibitors.